To determine the contribution of imaging agent activation from increased cathepsin-activity in the tumor compared with enhanced permeability and retention, we injected sarcoma-bearing mice (n = 4) with either Prosense 680 or a noncleavable Prosense 680 control and harvested tumor and muscle tissues 24 hours after injection. The gene discussed is CTSS; the disease is sarcoma.